GlassScriptPhysician profile
Ryan K Rogers
NPI 1356781124
$6,033.47
in general payments reported to CMS, 2019-2025
34 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,528 · 2022: $697 · 2023: $1,131 · 2024: $1,608 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,808.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,159.07 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $1,105.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $601.85 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Ucb, INC. | $433.05 | 2023-2024 | Nayzilam, Briviact |
| Biohaven Pharmaceuticals, INC. | $327.97 | 2021 | |
| Pfizer INC. | $271.29 | 2021-2025 | |
| Axsome Therapeutics, INC. | $265.16 | 2023-2025 | Auvelity, Symbravo |
| Lilly USA, LLC | $253.14 | 2021-2024 | Zepbound, Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $169.23 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Tris Pharma INC | $155.77 | 2021-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.59 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $108.85 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $100.86 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $91.83 | 2021-2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $84.04 | 2024-2025 | Voquezna |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $83.14 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.55 | 2022-2024 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $72.65 | 2023-2025 | Rexulti |
| Neurelis, INC. | $63.12 | 2023-2024 | Valtoco |
| Sage Therapeutics, LLC | $59.82 | 2025 | Zurzuvae |
| Biohaven Pharmaceutical Holding Company LTD. | $58.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.77 | 2021 | |
| Abbott Laboratories | $47.88 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.66 | 2022-2023 | |
| Corcept Therapeutics | $32.18 | 2025 | Korlym |
| Kaleo, INC. | $23.92 | 2022 | |
| Lundbeck LLC | $20.63 | 2025 | Vyepti |
| Vanda Pharmaceuticals INC. | $20.60 | 2025 | Hetlioz, Fanapt |
| Alexion Pharmaceuticals, INC. | $19.29 | 2021 | |
| Dexcom, INC. | $18.67 | 2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $16.17 | 2021 | |
| Sanofi Pasteur INC. | $15.84 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.71 | 2023 | Quviviq |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.